This prospective clinical trial evaluates whether HM-MRI identifies PCa more reliably than random biopsy and/or targets detected based on PI-RADSv2. Patients underwent 3T mpMRI along with HM-MRI. Patients received 12-core TRUS-guided sextant random biopsy. Additional biopsy targets selected by radiologist (≥PI-RADS 3) and suspected PCa based on HM-MRI tissue composition estimates were biopsied, using a Uronav MR-US fusion biopsy device. The diagnostic accuracy of HM-MRI for detecting clinically significant cancers was higher than that of mpMRI on per-tumor (0.74 vs 0.61) and sextant analysis (0.84 vs 0.75). HM-MRI had higher accuracy, sensitivity, specificity and PPV than mpMRI, with similar NPV.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords